Atossa Genetics Inc Soars On Distribution Pact With Henry Schein Inc.

Atossa Genetics Inc.

shares soared more than 40 percent Thursday after it signed an agreement with a major distributor for an upcoming launch of its FullCyte device used in breast examinations. http://ir.atossagenetics.com/press-releases/detail/694/henry-schein-medical-to-offer-atossa-genetics-fullcyte Seattle-based Atossa changed hands recently at $2.29, up $0.68 cents. Chief Executive Steven C. Quay called the distribution agreement, with Henry Schein Inc.

, an important step forward" in making the device available nationwide. Quay didn't offer a time table for the product launch. Atossa signed a similar distribution agreement for the product earlier this month with with Thermo Fisher Scientific Inc.

. http://ir.atossagenetics.com/press-releases/detail/674/atossa-genetics-signs-national-distribution-agreement-with The company said in November it planned a commercial launch of the FullCyte device " and a return to revenue generation in the near future."